Novartis Tells India Supreme Court Court 85% of Glivec Users Receive Free Doses
This article was originally published in PharmAsia News
Executive Summary
Swiss-based Novartis introduced an affidavit in its appeal to India's Supreme Court stating it had distributed free doses of its Glivec (imatinib) to 85% of the nation's cancer patients who relied on the treatment.